Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSV01 Injection in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07260812Phase 1Recruiting
- Sponsor
- TScan Therapeutics, Inc.
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSV01 in diffuse large B-cell lymphoma (DLBCL), sponsored by TScan Therapeutics, Inc. Primary endpoint: Dose-limiting Toxicity at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
KSV01
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07260812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260812.